{"id":11105,"date":"2020-08-31T17:32:00","date_gmt":"2020-08-31T15:32:00","guid":{"rendered":"https:\/\/idibell.cat\/en\/?page_id=11105"},"modified":"2024-01-09T14:34:58","modified_gmt":"2024-01-09T13:34:58","slug":"cell-plasticity-and-regeneration","status":"publish","type":"page","link":"https:\/\/idibell.cat\/en\/research\/area-medicina-regenerativa-english\/regenerative-medicine-program\/cell-plasticity-and-regeneration\/","title":{"rendered":"Cell Plasticity and Regeneration"},"content":{"rendered":"\n

\n\t\tCell Plasticity and Regeneration\n\t<\/h1>\n

\n\t\tSummary\n\t<\/h3>\n\t

We aim to improve quality of life for cancer survivors, which suffer side effects of radiotherapy including an acute and chronic inflammation of the intestine. In order to achieve this goal, we study the cellular and molecular mechanisms involved in epithelial recovery after radiation injury. Furthermore we study the establishment of the chronic radiation-induced enteritis with a particular attention to the epithelial-immune cell crosstalk.<\/p>\n

The primary function of the intestine is the digestion and absorption of nutrients. The small intestine is composed of proliferative crypts and differentiated villus structures. The adult intestine is lined with epithelium, which is maintained by intestinal stem cells. Radiation therapy is a common treatment used in at least 50% of cancer patients and despite its efficiency in eradicating cancer it induces intestinal toxicity. Radiation triggers apoptosis of proliferative cells, this denudes the intestinal mucosa and in turn results in an inflammatory response; the main features are initially an acute atrophy of the mucosa and at later stages fibrosis of the intestinal wall. The number of cancer survivors with post-radiation dysfunction of intestinal epithelium is continuously rising. However this condition to date has no effective treatments. Our primary objective is to understand the mechanisms triggering these processes in order to develop therapeutic options for those patients. In order to achieve this goal we use state of the art technologies and a plethora of groundbreaking approaches such as patient derived intestinal organoids, complemented by mouse models, lineage tracing, single cell transcriptomics and 3-dimensional imaging.<\/p>\n

21<\/h2>\n

Publications<\/h2>\n\t\t\t\t\"GuiuLab600x300\"\n\t\t\t\t\tStrategic lines<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

-Study tissue heterogeneity in acute and chronic enteritis.<\/p>\n

-Elucidate the role of immune cells in radiation-induced enteritis<\/p>\n

-Identify strategies to boost epithelial regeneration.<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n\t\t\t\t\tSelected publications<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Guiu J, Jensen KB. Rebuttal to: Organoid vs Mouse Model<\/strong>: Which is a Better Research Tool to Understand the Biologic Mechanisms of Intestinal Epithelium?<\/strong>. Cell. Mol. Gastroenterol. Hepatol. 2022;13(1):193-193. doi:10.1016\/j.jcmgh.2021.09.011.<\/p>\n

Guiu J, Jensen KB. In vivo studies should take priority when defining mechanisms of intestinal crypt morphogenesis<\/strong>. Cell. Mol. Gastroenterol. Hepatol. 2022;13(1):1-3. doi:10.1016\/j.jcmgh.2021.06.028.<\/p>\n

Taelman J, Diaz M, Guiu J. Human Intestinal Organoids: Promise and Challenge<\/strong>. Front. Cell. Dev. Biol. 2022;10854740-854740. doi:10.3389\/fcell.2022.854740.<\/p>\n

Martti Maimets, Marianne Terndrup Pedersen, Jordi Guiu, Jes Dreier, Malte Thodberg, Yasuko Antoku, Pawel J Schweiger, Leonor Rib, Raul Bardini Bressan, Yi Miao, K Christopher Garcia, Albin Sandelin, Palle Serup, Kim B Jensen. Mesenchymal-epithelial crosstalk shapes intestinal regionalisation via Wnt and Shh signalling<\/strong>. Nature Communications. 2022. doi: 10.1038\/s41467-022-28369-7<\/p>\n\n\t\t\t\t\tSelected Projects<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

FIS21074. DESARROLLANDO TERAPIAS PARA SOBREVIVIENTES DE C\u00c1NCER <\/strong>(CanCARE). DEVELOPING THERAPIES FOR CANCER SURVIVORS (CanCARE)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 379822,63. 2022-2024. PI: Guiu Sagarra, Jordi.<\/p>\n

21FIS006. Miguel Servet I<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 242500. 2021-2024. PI: Guiu Sagarra, Jordi.<\/p>\n

FIS22103. Acciones Individuales MSCA – Sello de Excelencia ISCIII-HEALTH<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 163728,68. 2023-2024. PI: Guiu Sagarra, Jordi.<\/p>\n

PUB22017. INVESTIGO 2022<\/strong> – GUIU, JORDI. SERVICIO PUBLICO DE EMPLEO ESTATAL SEPE. Budget: 66217,68. 2022-2024. PI: Guiu Sagarra, Jordi.<\/p>\n\t\t\t\t\"Jordi-Guiu22\"\n

\n\t\tGuiu Sagarra, Jordi\n\t<\/h4>\n

\n\t\t\n\t\tjguiu@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tPrincipal investigators\n\t<\/h2>\n\t\t\t\t\"Jordi-Guiu22\"\n

\n\t\tGuiu Sagarra, Jordi\n\t<\/h4>\n

\n\t\t\n\t\tjguiu@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tRELATED LINKS\n\t<\/h4>\n

\n\t\t\n\t\t@GuiuLab\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tORCID\n\t\t<\/a>\n\t<\/h6>\n
\n\t\t\n\t\tGoogle Scholar\n\t\t<\/a>\n\t<\/h6>\n

\n\t\tTeam\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tGroup leader\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPostdoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tPredoctoral researchers\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tScientific support\t\t\t\t<\/a>\n\t\t\t\t\t\tGroup leader\n\t\t\t\t\t\t\t\t\t\t\t